Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of a vaccination campaign with A(H1N1)v pandemic vaccines: a prospective cohort study
2009-015700-26Phase 3Completed
- Sponsor
- Thomas H. Lee Partners
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in H1N1 influenza (H1N1) (2 arms), sponsored by Thomas H. Lee Partners. Primary endpoints: Effectiveness: first episode of laboratory-confirmed A(H1N1)v influenza and Safety over 6 months after A(H1N1)v vaccination. Started Sep 2009; status: completed.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
H1N1 influenza (H1N1)
Beyond the preview
Go deeper on 2009-015700-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015700-26.